Changing the Course of Disease in Lupus
A Science & Innovation Webinar, sponsored by GSK.
Patients with systemic lupus erythematosus (SLE) can present with diverse signs and symptoms. SLE is a disease of waxing and waning activity and progressive organ damage. Serious manifestations of the disease, such as lupus nephritis, can increase the risk of flares and loss of kidney function and early end-stage kidney disease. Mean all-cause healthcare costs increase as patients incur organ damage. Impacting disease pathophysiology and drug can modify the natural course of disease and prevent future organ damage.
By the end of the program, participants will be able to:
- Review the pathophysiology, clinical manifestations, and disease course of lupus.
- Describe the importance and key components of disease modification in lupus.
- Discuss treatment goals and outcomes assessments focused on changing the course of disease.
Speaker:
- Maria Dall'Era, MD
Professor and Chief, UCSF, Division of Rheumatology
Director, UCSF Lupus Clinic and Rheumatology Clinical Research Center
Jean S. Engleman Distinguished Professor in Rheumatology
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
Sponsored by:
For individuals from the media/press who are interested in attending, please email media@amcp.org.
